Guggenheim Rates AbbVie (ABBV) Buy, $288 Price Target

Guggenheim has reaffirmed its Buy rating on AbbVie with a price target of $288, a 0.87% upside from the current price.

By EarningsIQ Research Desk · Published Oct 16, 2026, 1:55 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Guggenheim rated AbbVie Inc. ($ABBV) "Buy" with a $288 price target on October 9, 2026.

Since the rating, $ABBV is up 3.9% after 1 week and up 3.9% to date (from the $274.78 close on Oct 9, 2026).

ABBV AbbVie Inc.

$285.42 +28.19% year to date

Daily close · Oct 16, 2026

Key Points

On October 9, 2026, Guggenheim reiterated its Buy rating on AbbVie Inc. (NYSE: ABBV) with a price target of $288.
Guggenheim's $288 price target implies 0.87% upside from AbbVie Inc.'s ($ABBV) current $285.52 share price.
Shares of AbbVie recently traded around $285.52, which is about 0.9% below the analyst's target.
Other analysts also maintain positive ratings, with Morgan Stanley and JP Morgan both keeping Overweight ratings and targets of $310 and $300, respectively.

Get $ABBV trade alerts by text

We text you when insiders, Congress or big funds trade $ABBV. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated AbbVie Inc. alert may contain errors. Disclosures

Guggenheim has reiterated its Buy rating on AbbVie Inc. (NYSE: ABBV) with a price target of $288 on October 9, 2026. This call comes as other analysts also show confidence in the stock, maintaining their positive outlooks.

Other Institutional Activity in AbbVie

Blackrock Inc. trimmed its holdings by 1,205,552 shares, leaving it with 149,488,412 shares valued at about $42.7 billion. Vanguard Capital Management LLC added 516,956 shares, increasing its total to 115,396,098 shares worth approximately $32.9 billion. State Street Corporation grew its stake by 1,380,673 shares, bringing its total to 82,596,748 shares valued at around $23.6 billion. Meanwhile, Vanguard Portfolio Management LLC reduced its holdings by 1,044,934 shares, ending with 48,477,996 shares worth about $13.8 billion. JPMorgan Chase & Co. cut its position by 8,880,294 shares, now holding 47,862,796 shares valued at about $13.7 billion.

AbbVie Inc. Stock Up 0.7%

AbbVie shares recently traded around $285.52, which is about 0.9% below Guggenheim's target of $288. This comes as the stock has been performing steadily, and the recent price is a good indicator of its position relative to analyst expectations.

12-month forecast

$ABBV price target

AbbVie Inc. daily closes and this analyst's $288 target. Not advice.

Recent Earnings

AbbVie reported trailing twelve-month revenue of approximately $64.4 billion, reflecting a year-over-year revenue growth of 10.2%. The company has an EPS of $3.54 and a net margin of 9.8%. AbbVie is scheduled to announce its next earnings on October 29, 2026.

Earnings drift grade

Outlook vs expectations on the last report — not price action.

C+ 65/100

Reported Apr 29, 2026

Forward outlook
4 analysts raised price targets.
EPS & revenue
EPS met estimates. Revenue met estimates.
Profit surprise
EBITDA missed by 42 percent. Operating income missed by 72 percent.
Pre-earnings setup
Expectations were about average.
Analyst signal
4 target raises.
Earnings quality
Gross margin up 1.9 points. Operating margin up 3.6 points. Positive free cash flow.

Earnings Call Summary

AbbVie delivered strong first quarter results with $15 billion in sales and earnings per share of $2.65, beating expectations. Skyrizi sales hit $4.5 billion with 29 percent growth in psoriasis and inflammatory bowel disease markets. Rinvoq brought in $2.1 billion with 20 percent growth across rheumatology and gastroenterology, and the company is preparing to launch the drug in alopecia areata and vitiligo later this year.

Guidance The company raised full year earnings per share guidance to between $14.08 and $14.28, up $0.12. They now expect about $67.3 billion in total sales for the year. They also raised guidance for second quarter to about $16.7 billion in revenue and earnings per share between $3.74 and $3.78.

Fine but not compelling. Acceptable results that likely do not create a meaningful forward reset.

Insider Buying and Selling at AbbVie Inc.

Several insiders have sold shares of AbbVie, including Perry C. Siatis, the General Counsel, who sold 22,381 shares at an average price of $230 on February 25, 2026, totaling around $5.1 million. Siatis also sold another 18,668 shares on March 2, 2026, valued at approximately $4.4 million. Officer David Ryan Purdue sold 5,230 shares at $233.56 on March 4, 2026, worth about $1.2 million. Additionally, Nicholas Donoghoe, another officer, sold 32,710 shares at $250 on August 14, 2026, totaling about $8.2 million.

Analysts Set New Price Targets

On October 7, 2026, Morgan Stanley maintained an Overweight rating with a target of $310, while JP Morgan also kept an Overweight rating, raising its target from $285 to $300 on October 8. Cantor Fitzgerald maintained an Overweight rating with a target of $290 on the same day. On October 9, UBS maintained a Neutral rating with a target of $275.

About AbbVie

AbbVie Inc. is a research-based biopharmaceutical company based in North Chicago, Illinois. It focuses on developing, manufacturing, and selling a range of medicines and therapies worldwide. The company is known for its treatments for autoimmune diseases, blood cancers, and various types of cancer.

Bottom Line

Investors should keep an eye on AbbVie as it approaches its next earnings report on October 29, 2026. With Guggenheim's reaffirmation of a Buy rating and other analysts maintaining positive outlooks, the stock remains a focal point in the healthcare sector.